Glutamine depletion impairs cellular stress response in human leucocytes.
During sepsis and major trauma the blood glutamine (Gln) level is reduced. The administration of Gln can improve the outcome of these patients. However, the mechanism of this beneficial effect of Gln is poorly understood. In the course of critical illness leucocytes are confronted with cytotoxic inflammatory mediators. To protect themselves against these factors, cells express heat shock proteins (HSP). Previous studies have shown that the expression of the major inducible HSP (HSP70) is improved by high Gln concentrations above 4 mM. In this study we investigated whether Gln depletion, such as observed during critical illness, has an effect on HSP70 expression. Human lymphocytes exposed for 2 h to 42 degrees C showed a 3-fold increase in HSP70 expression (P<0.01). A preceding Gln starvation period over 3 days had no influence on this increase. However, when Gln is reduced during the stress response, HSP70 expression is impaired. A reduction of Gln from 0.5 mM (physiological) to 0.125 mM (pathological) led to a 40% lower HSP70 level (P<0.002). In contrast, increasing Gln concentrations (up to 2 mM) had only minor stimulatory effects (about 15%). This Gln-dependency of heat mediated HSP70 expression was observed in resting as well as proliferating lymphocytes. Our data indicate that during periods of reduced plasma Gln levels the stress response of human lymphocytes is impaired. Thus, Gln may be essential to minimize the susceptibility of leucocytes to cytotoxic inflammatory mediators. This is a new aspect of the protective effect of Gln supplementation in critically ill patients.
Oehler
Rudolf
R
Surgical Research Laboratories, University of Vienna, Austria. rudolf.oehler@akh-wien.ac.at
Pusch
Erich
E
Dungel
Peter
P
Zellner
Maria
M
Eliasen
Maja Munk
MM
Brabec
Marianne
M
Roth
Erich
E
D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D005973:Glutamine / Q000172:deficiency / Q000494:pharmacology / Q000502:physiology*; D018840:HSP70 Heat-Shock Proteins / Q000097:blood*; D018869:Heat-Shock Response / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*
D018840:HSP70 Heat-Shock Proteins; D005973:Glutamine